[go: up one dir, main page]

TN2009000551A1 - Nouveaux composes chimiques - Google Patents

Nouveaux composes chimiques

Info

Publication number
TN2009000551A1
TN2009000551A1 TNP2009000551A TN2009000551A TN2009000551A1 TN 2009000551 A1 TN2009000551 A1 TN 2009000551A1 TN P2009000551 A TNP2009000551 A TN P2009000551A TN 2009000551 A TN2009000551 A TN 2009000551A TN 2009000551 A1 TN2009000551 A1 TN 2009000551A1
Authority
TN
Tunisia
Prior art keywords
chemical compounds
new chemical
compounds
drug
excessive
Prior art date
Application number
TNP2009000551A
Other languages
English (en)
Inventor
Ioannis Sapountzis
Peter Ettmayer
Christian Klein
Andrea Mantoulidis
Steffen Steurer
Irene Waizenegger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2009000551A1 publication Critical patent/TN2009000551A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés de formule générale (1), dans laquelle R1 à R3 et L sont définis dans la revendication 1, qui sont appropriés pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale, et leur utilisation pour préparer un médicament possédant les propriétés mentionnées ci-dessus.
TNP2009000551A 2007-07-02 2009-12-31 Nouveaux composes chimiques TN2009000551A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07111566 2007-07-02
PCT/EP2008/058433 WO2009003999A2 (fr) 2007-07-02 2008-07-01 Nouveaux composés chimiques

Publications (1)

Publication Number Publication Date
TN2009000551A1 true TN2009000551A1 (fr) 2011-03-31

Family

ID=38792475

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000551A TN2009000551A1 (fr) 2007-07-02 2009-12-31 Nouveaux composes chimiques

Country Status (21)

Country Link
US (1) US8889665B2 (fr)
EP (1) EP2173734B1 (fr)
JP (1) JP5511658B2 (fr)
KR (1) KR20100039849A (fr)
CN (1) CN101796045A (fr)
AR (1) AR067397A1 (fr)
AU (1) AU2008270300A1 (fr)
BR (1) BRPI0814601A2 (fr)
CA (1) CA2692383A1 (fr)
CL (1) CL2008001943A1 (fr)
CO (1) CO6251316A2 (fr)
EA (1) EA201000105A1 (fr)
EC (1) ECSP099823A (fr)
IL (1) IL202625A0 (fr)
MA (1) MA32120B1 (fr)
MX (1) MX2009013935A (fr)
PE (1) PE20090837A1 (fr)
TN (1) TN2009000551A1 (fr)
TW (1) TW200911789A (fr)
UY (1) UY31198A1 (fr)
WO (1) WO2009003999A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200900072A1 (ru) 2006-07-07 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2692379A1 (fr) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Nouveaux composes chimiques
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
WO2010034838A2 (fr) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh Nouveaux composés chimiques
EP2398797B1 (fr) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Dérivés des pyrimido[5,4-d]pyrimidine pour l'inhibition des tyrosine kinases
JP2010235575A (ja) * 2009-03-09 2010-10-21 Konica Minolta Holdings Inc 含窒素縮合複素環化合物の製造方法
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
EP2552907B1 (fr) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2013018695A1 (fr) 2011-07-29 2013-02-07 武田薬品工業株式会社 Composé hétérocyclique
CN103172617A (zh) * 2011-12-20 2013-06-26 天津市国际生物医药联合研究院 1,5-二取代-1,2,3-三氮唑三氟甲基类化合物的应用
CN103539784B (zh) * 2012-07-09 2016-08-17 中国科学院广州生物医药与健康研究院 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143654A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
AU2016275764B8 (en) 2015-06-11 2021-03-04 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
KR101723881B1 (ko) * 2016-03-28 2017-04-07 이화여자대학교 산학협력단 신규한 트리아졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 오로라 키나제 관련 약학적 조성물
EP3817811B1 (fr) * 2018-07-04 2024-04-03 Boehringer Ingelheim International GmbH Dérivés de triazole benzamide en tant qu'agonistes de gpr142
EP4146633A4 (fr) * 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. Composition destinée à être utilisée dans le traitement d'une maladie associée à apol1
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
CN119300807A (zh) * 2022-04-19 2025-01-10 沃特谢德医疗公司 用于治疗泌尿系统紊乱的制剂
CN114805334B (zh) * 2022-05-24 2023-06-09 深圳大学 一种QC和GSK-3β多靶向抑制剂及其制备方法与应用
WO2024149728A1 (fr) * 2023-01-10 2024-07-18 Astrazeneca Ab (hétéro)anilines substituées et leur utilisation
CN116068110B (zh) * 2023-01-19 2024-11-22 武汉大学 叠氮质谱探针的合成方法及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU507066B1 (en) 1977-09-06 1980-01-31 Sumitomo Chemical Company, Limited 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja) 1989-09-20 1991-07-29 Fuji Photo Film Co Ltd カラー画像形成方法
ATE197300T1 (de) 1995-02-02 2000-11-15 Smithkline Beecham Plc Indolderivate als 5-ht rezeptorantagoniste
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
WO2000047194A2 (fr) 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE MALADIES ET PATHOLOGIES INDUITES PAR C1s, COMPOSES ET COMPOSITIONS PREPARES A CET EFFET
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2002069070A (ja) * 2000-04-07 2002-03-08 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1364949A4 (fr) 2001-02-02 2005-11-23 Takeda Pharmaceutical Inhibiteur de jnk
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
AU2003294388A1 (en) 2002-11-27 2004-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. 1, 2, 3- triazole amide derivatives as cytokine inhibitors
CA2538820A1 (fr) 2003-09-11 2005-03-17 Kemia, Inc. Inhibiteurs des cytokines
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2005040152A1 (fr) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Azolecarboxamides substitues par heterocyclylphenyle et heterocyclylpyridile
WO2005056535A1 (fr) * 2003-12-03 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 1,2,3-triazole amide servant d'inhibiteurs de la production de cytokines
PT1725544E (pt) 2004-03-09 2009-07-02 Boehringer Ingelheim Pharma 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
EP1819341A4 (fr) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp Composes modulateurs de la il-12
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
ES2465469T3 (es) * 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (fr) 2005-11-02 2007-05-18 Kemia, Inc. Inhibiteurs de cytokine bisamide
WO2007075896A2 (fr) 2005-12-22 2007-07-05 Kemia, Inc. Inhibiteurs de cytokine heterocycliques
US20070155746A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
JP2009536618A (ja) * 2006-04-18 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−及び５−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
EA200900072A1 (ru) 2006-07-07 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
CA2657051A1 (fr) 2006-07-07 2008-01-10 Schering Corporation Cyclobutene-1,2-diones 3,4-disubstituees utilisees comme ligands de recepteur de chimiokine cxc
WO2008008234A1 (fr) 2006-07-07 2008-01-17 Targegen, Inc. Inhibiteurs de type 2-amino-5-substituant-pyrimidines
BRPI0714359A2 (pt) 2006-07-07 2013-02-26 Bristol-Myers Squibb Company inibidores de pirrolotriazina cinase
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2008089034A2 (fr) 2007-01-11 2008-07-24 Kemia, Inc. Inhibiteurs de cytokine
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
CA2692379A1 (fr) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Nouveaux composes chimiques
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PL2324008T3 (pl) 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
WO2010034838A2 (fr) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh Nouveaux composés chimiques
EP2398797B1 (fr) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Dérivés des pyrimido[5,4-d]pyrimidine pour l'inhibition des tyrosine kinases
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
EP2552907B1 (fr) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
EA201000105A1 (ru) 2010-06-30
CO6251316A2 (es) 2011-02-21
MA32120B1 (fr) 2011-03-01
US20110183952A1 (en) 2011-07-28
CN101796045A (zh) 2010-08-04
WO2009003999A2 (fr) 2009-01-08
PE20090837A1 (es) 2009-07-24
JP5511658B2 (ja) 2014-06-04
US8889665B2 (en) 2014-11-18
JP2010531851A (ja) 2010-09-30
CA2692383A1 (fr) 2009-01-08
WO2009003999A3 (fr) 2009-07-16
ECSP099823A (es) 2010-01-29
AR067397A1 (es) 2009-10-07
MX2009013935A (es) 2010-01-28
BRPI0814601A2 (pt) 2019-09-24
EP2173734B1 (fr) 2016-03-23
IL202625A0 (en) 2010-06-30
CL2008001943A1 (es) 2009-09-11
TW200911789A (en) 2009-03-16
EP2173734A2 (fr) 2010-04-14
KR20100039849A (ko) 2010-04-16
UY31198A1 (es) 2009-01-30
AU2008270300A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
TN2009000551A1 (fr) Nouveaux composes chimiques
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA30514B1 (fr) Nouveaux composes.
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA32506B1 (fr) Nouveaux composes
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MA41625A (fr) Composés de benzazépine dicarboxamide
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA33737B1 (fr) Dérivés de glycoside et utilisations de ceux-ci
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA32158B1 (fr) Thiazolyldihydroindazoles
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
TW200509892A (en) Novel aminobenzophenone compounds